Standout Papers

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC... 2019 2026 2021 2023 299
  1. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019)
    Jhanelle E. Gray, Augusto Villegas et al. Journal of Thoracic Oncology

Immediate Impact

1 by Nobel laureates 62 standout
Sub-graph 1 of 22

Citing Papers

Advances in diagnosis and treatment of bladder cancer
2024 Standout
Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
2 intermediate papers

Works of Catherine Wadsworth being referenced

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
2019 Standout
Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
2018

Author Peers

Author Last Decade Papers Cites
Catherine Wadsworth 426 406 50 72 17 540
Kobe Reynders 376 208 64 164 12 528
Maria Cristina Bruna 234 254 119 97 13 471
Patrick M. Travis 228 343 35 27 10 472
Catherine Dubos‐Arvis 296 337 36 25 11 462
Junliang Cai 441 387 51 60 12 516
Pooja Patel 220 188 57 50 13 461
A. Vincent 175 456 50 40 17 647
Christian Stremmel 216 281 117 101 25 632
Kenji Nakahama 440 306 51 49 29 504
Daniel Nicastri 194 444 132 18 22 616

All Works

Loading papers...

Rankless by CCL
2026